BriaCell adds Penn Medicine as Phase 3 breast cancer study site

BriaCell (BCTX) Therapeutics has added Penn Medicine’s Abramson Cancer Center as a clinical trial site in its ongoing pivotal Phase 3 study evaluating Bria-IMT in combination with an immune checkpoint inhibitor versus physician’s choice of treatment in advanced breast cancer. Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia Comprehensive Cancer Center, Baptist Health South Florida, and SCRI Oncology Partners. The Bria-IMT combination regimen has received FDA Fast Track designation.